We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · July 09, 2019

Trastuzumab Duocarmazine in Locally Advanced and Metastatic HER2-Expressing Breast Cancer

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Trastuzumab Duocarmazine in Locally Advanced and Metastatic Solid Tumours and HER2-Expressing Breast Cancer: A Phase 1 Dose-Escalation and Dose-Expansion Study
Lancet Oncol 2019 Jun 27;[EPub Ahead of Print], U Banerji, CML van Herpen, C Saura, F Thistlethwaite, S Lord, V Moreno, IR Macpherson, V Boni, C Rolfo, EGE de Vries, S Rottey, J Geenen, F Eskens, M Gil-Martin, EC Mommers, NP Koper, P Aftimos

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading